Journal article
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
- Abstract:
-
The clinical benefit of adding FMS-like tyrosine kinase-3 (FLT3)-directed small molecule therapy to standard first-line treatment of acute myeloid leukemia (AML) has not yet been established. As part of the UK AML15 and AML17 trials, patients with previously untreated AML and confirmed FLT3-activating mutations, mostly younger than 60 years, were randomly assigned either to receive oral lestaurtinib (CEP701) or not after each of 4 cycles of induction and consolidation chemotherapy. Lestaurtin...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 599.1KB)
-
- Publisher copy:
- 10.1182/blood-2016-07-730648
Authors
Funding
UK Medical Research Council
More from this funder
Bibliographic Details
- Publisher:
- American Society of Hematology Publisher's website
- Journal:
- Blood Journal website
- Volume:
- 129
- Issue:
- 9
- Pages:
- 1143-1154
- Publication date:
- 2017-03-02
- Acceptance date:
- 2016-11-06
- DOI:
- EISSN:
-
1528-0020
- ISSN:
-
0006-4971
- Pmid:
-
27872058
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:930218
- UUID:
-
uuid:3659ad0e-5e69-47ee-851b-9cc81052e2c4
- Local pid:
- pubs:930218
- Source identifiers:
-
930218
- Deposit date:
- 2019-02-27
Terms of use
- Copyright holder:
- American Society of Hematology
- Copyright date:
- 2017
- Notes:
- © 2017 by The American Society of Hematology. This is the accepted manuscript version of the article. The final version is available online from the American Society of Hematology at: https://doi.org/10.1182/blood-2016-07-730648
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record